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Table 2
Patient outcomes
Characteristic Number/Median (range)
Days to Neutrophil engraftment 9 (7-15)
Days to Platelet engraftment 16 (11-230)
Complication
Oral mucositis 23
Hyperbilirubinemia 10
Hypertension 12
Sinusoidal obstruction syndrome (SOS)* 1
Infections (number of patients) 26
- Bacterial 11
- Viral 21
- Fungal 3
GVHD
Acute GVHD
- Acute Gr I-II 4
- Acute Gr III-IV 0
Chronic GVHD
- Chronic, limited 3
- Chronic, extensive 0
Fig 1. One-year probabilities of overall survival and disease free survival.
Abstracts / Biol Blood Marrow Transplant 21 (2015) S79eS107S104multiorgan failure) are alive with a median follow up of 2
years (range, 10 dayse5 years) and a 3-yr OS by KaplanMeier
analysis of 96% (95%CI: 73%-99%). All patients with viral in-
fections at the time of transplant cleared the infection at a
median time of 51 days (range, 44-54). ELISPOT analyses of
peripheral blood at the time that infections responded
showed signiﬁcant T cell responses against the pertinent vi-
ruses. All evaluable patients have normalization of their im-
mune or metabolic defect including adequate B cell function
in SCID patients. Hence, UCBTafter full intensity conditioning
without serotherapy forpediatricnon-malignantdiseases can
produce rapid functional engraftment and immune-recon-
stitution in the absence of signiﬁcant GVHD, leading to
excellent overall survival.
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Objective: This multi-institutional study was designed to
optimize outcomes of alternative donor HCT in patients with
FA without using total body irradiation (TBI). TBI was
replaced by busulfan (BU) (to reduce the risk of secondary
solid tumors) and BU dose was reduced after ﬁrst 25 patients
to ﬁnd the lowest acceptable BU dose.
Methods: 45 patients were transplanted from June 2009 to
May 2014. These included patients with prior transfusions,
androgen use and myelosdysplastic syndrome. Patient de-
mographics, disease and donor characteristics are described
in Table 1.Table 1
Patient demographics
Characteristics Number/Median (Range)
Median age in years 8.2 (4.3-44)
<10 years of age 27
10 years of age 18
Gender
- Males 20
- Females 25
Severe Single Lineage Cytopenia 5
Severe Aplastic Anemia 29
Myelodysplastic Syndrome 11
- Low grade 7
- High grade 4
Donor type
Matched Unrelated (8/8 match) 25
Mismatched Unrelated (7/8 match) 14
Mismatched Related (4/8, 5/8, 6/8 match) 5
Phenotypically Matched Related (8/8) 1
Follow-up in months, Median and Range 21.3 (2.6 - 61)Preparative regimen included: BU (BU) 0.8-1.0 mg/Kg/
dose IV (ﬁrst 25 patients) and 0.6-0.8 mg/kg/dose Q 12H
(next 20 patients) x 4 doses, cyclophosphamide (10mg/kg/
dose), ﬂudarabine (35mg/m2/dose) and rabbit ATG(2.5mg/
kg/dose) daily x 4 days. BU doses were adjusted based on
pharmacokinetics of the ﬁrst dose. All grafts were T-cell
depleted using the CliniMacs CD34 columns (Miltenyi).
GvHD prophylaxis was cyclosporine.
Results: 43patientsengrafted.Onepatienthad lategraft failure
and one had early relapse of MDS. See Table 2 for detailed
results and transplant outcomes. One patient (#3) developed
sinusoidal obstruction syndrome of liver. However, after
reducing the BU goal level, no further SOS observed.
36 of the 45 patients are alive. Causes of death included
infection (n¼5), multi-organ failure (n¼3), and severe pul-
monary hypertension (n¼1). One year probability of overall
and disease free survival for the entire cohort was 79.2%
(+/-6.2%) and 76.7 (+/-6.5%) respectively (Fig 1). OS for pa-
tients <10 years of age transplanted for marrow failure was
91.3% (+/-5.9%) similar to that reported for historical matched
sibling donor HCT outcomes.
Conclusion: This chemotherapy only preparative regimen
leads to excellent outcomes in patients undergoing
Figure.
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based protocols, while avoiding short and (to date) long-
term toxicity associated with radiation.104
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The human gut microbiome is involved in vital biological
functions such as maintenance of immune homeostasis,
modulation of intestinal development and enhanced meta-
bolic capabilities. Disturbances of intestinal microbiota have
been associated with development and progression of in-
ﬂammatory conditions including GVHD. Non-secretor in-
dividuals do not express the H antigen on mucosal surfaces
and body ﬂuids due to a homozygous single nucleotide
polymorphism in the fucosyltransferase 2 (FUT2) gene
(428G>A) and FUT2 genotype has been shown to modify the
gut microbiome. We hypothesized that FUT2 genotype in-
ﬂuences risk of GVHD and bacterial translocation following
allogeneic HSCT.
FUT2 genotype was determined in 150 consecutive patients
receiving allogeneic HSCT at our center. We abstracted clin-
ical characteristics and outcomes from the transplant
database.
Median age at transplantationwas 6.31 years andmale/female
ratio was 97/53. Genetic analysis revealed 23% recipients had
A/A genotype (n¼34), 52% A/G genotype (n¼78) and 25% G/G
genotype (n¼38); Hardy Weinberg equilibrium was con-
ﬁrmed. Hematologicmalignancies comprised 30% (n¼45), 29%
immune deﬁciencies (n¼43), 22% bonemarrow failure (n¼33),
12% hemophagocytic lymphohistiocytosis (HLH) (n¼18), 4%
metabolic diseases (n¼6), 3% hemoglobinopathies (n¼4), and
one patient with Evan’s syndrome. 54% receivedmyeloablative
conditioning (n¼81), while 46% received reduced intensity
conditioning (n¼68). Stem cell source was bone marrow in
81% (n¼122), peripheral blood stem cells in 11% (n¼16), cord
blood in 7% (n¼11), and one patient received both bone
marrow and cord blood from a sibling donor. Among donors,29% were matched sibling donors (n¼43), 49% matched un-
related or other family member donors (n¼74) and 22% were
mismatched donors (n¼33). Acute GVHD occurred in 36% of
patients (n¼54). Cumulative risk of any acute GVHD varied by
FUT2 genotypewith decreased risk in thosewith A/A genotype
and increased risk in those with G/G genotype (p¼0.04) (Fig.
1). A/A genotype (OR¼0.4 p-value¼0.046), myeloablation
(OR¼1.99 p-value¼0.029) and matched sibling donor
(OR¼0.41 p-value¼0.026) were identiﬁed to be signiﬁcant
GVHD risk factors in multivariate analysis. Bacteremia
occurred in 34% of patients (n¼51), and in contrast to our
ﬁndings in GVHD cumulative incidence was increased in A/A
genotype (p-value¼0.01) (Fig. 1). A/A genotype (OR¼3.94 p-
value¼0.0047) and A/G genotype (OR¼2.46 p-value¼0.05)
were associated with increased risk in multivariate analysis.
FUT2 genotype inﬂuences risk of acute GVHD and bacteremia
following HSCT. We hypothesize that the mechanism in-
volves altered composition and diversity of gut microbiome,
and limited data indicate increased diversity of the gut
microbiome in the A/A genotype, but this requires additional
studies.105
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Introduction: AutoHCT is a potentially curative modality for
Rel/Ref HL. However, large studies evaluating the risk factors
predicting outcomes of autoHCT in CAYA with Rel/Ref HL
have not been performed.
